MOSCOW, April 7. /TASS/. Russia’s Vector Center has received a flurry of requests from abroad so far for the EpiVacCorona anti-coronavirus jab and similar appeals keep pouring in, but providing enough doses of the vaccine for Russians remains a priority, Chief of Vector’s Yekaterinburg Research Institute of Viral Infections Alexander Semyonov told the Vesti FM radio station on Wednesday.
"There have been many requests but our priority is to produce enough vaccines for the citizens of Russia and allied countries. Then we will think about fulfilling overseas requests. We have quite a few of them," he stressed.
EpiVacCorona, developed by the State Research Center of Virology and Biotechnology Vector under the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, was the second vaccine to have been certified in Russia. This occurred on October 14, 2020. About one month later, the developers were allowed to carry out post-registration research, including tests on seniors.